JWCAR239 cell therapy for B cell non-Hodgkin lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests an experimental treatment called JWCAR239, which uses your own immune cells (T cells) that are modified in a lab to find and kill lymphoma cells. It is for people with certain types of B cell lymphoma that have come back or not responded to at least two prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of B cell lymphoma that tests positive for CD20 or CD19 proteins.
- Your lymphoma has come back or not responded to at least two prior treatments, or a stem cell transplant using your own cells has failed.
- You have at least one tumor that can be measured on a CT scan or PET scan.
- You are physically active and able to care for yourself (ECOG score of 0 or 1).
- Your organs (bone marrow, kidneys, liver, lungs, heart) are working well enough, as checked by blood tests and other exams.
- You have not had certain treatments (like specific chemotherapies or antibody therapies) within a specific timeframe before joining.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new treatment called CD19x22 CAR T cells for people with certain types of B-cell lymphoma that have come back or not responded to other treatments. The therapy uses your own immune cells, which are modified in a lab to better attack the cancer.
This trial tests a new kind of immune cell therapy for people with certain types of lymphoma that have come back or not responded to previous treatments. The cells are made from your own blood and are designed to find and attack the cancer cells.
This trial tests a new type of CAR T-cell therapy that targets three proteins (CD19, CD20, and CD22) on lymphoma cells. It's for people with B-cell lymphomas that have come back or not responded to at least two prior treatments.
This trial tests a new treatment called JCXH-213 for people with B-cell non-Hodgkin lymphoma that came back or didn't get better after previous treatment. It aims to see if the treatment is safe and works against the cancer.
This trial tests a new treatment made from your own immune cells (gamma-delta T cells) that are engineered to find and kill CD19-positive lymphoma cells. It is for people with B-cell non-Hodgkin lymphoma whose cancer has not responded to or has returned after at least two standard treatments.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called CD19 on your lymphoma cells. It's for people whose B-cell lymphoma has returned or not responded to standard treatments.
Hear when a new B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.